Total Payments
$2.9M
2024 Payments
$103,990
Companies
90
Transactions
4,207
Medicare Patients
20,740
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$1.8M (61.3%)
Travel$420,913 (14.4%)
Consulting$324,444 (11.1%)
Research$263,157 (9.0%)
Food & Beverage$81,747 (2.8%)
Royalty/License$40,000 (1.4%)
Education$206.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 790 | 58.3% |
| Travel and Lodging | $420,913 | 944 | 14.4% |
| Consulting Fee | $324,444 | 80 | 11.1% |
| Unspecified | $263,157 | 26 | 9.0% |
| Food and Beverage | $81,747 | 2,312 | 2.8% |
| Honoraria | $66,000 | 22 | 2.3% |
| Royalty or License | $40,000 | 1 | 1.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $20,001 | 17 | 0.7% |
| Education | $206.80 | 15 | 0.0% |
Payments by Type
General
$2.7M
4,181 transactions
Research
$263,157
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $542,869 | 621 | $0 (2024) |
| Novo Nordisk Inc | $498,419 | 633 | $0 (2024) |
| Lilly USA, LLC | $338,252 | 461 | $0 (2024) |
| Novo Nordisk AS | $252,944 | 88 | $0 (2023) |
| Eli Lilly and Company | $203,982 | 25 | $0 (2024) |
| Medtronic MiniMed, Inc. | $178,453 | 350 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $144,115 | 188 | $0 (2020) |
| Mannkind Corporation | $129,278 | 285 | $0 (2024) |
| Senseonics, Incorporated | $108,675 | 66 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $89,482 | 151 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $103,990 | 285 | Lilly USA, LLC ($53,365) |
| 2023 | $284,509 | 411 | SANOFI US SERVICES INC. ($68,535) |
| 2022 | $265,522 | 439 | Novo Nordisk Inc ($71,378) |
| 2021 | $299,231 | 514 | Lilly USA, LLC ($82,455) |
| 2020 | $283,632 | 447 | Lilly USA, LLC ($86,637) |
| 2019 | $445,022 | 621 | Novo Nordisk Inc ($100,976) |
| 2018 | $538,906 | 647 | SANOFI-AVENTIS U.S. LLC ($130,988) |
| 2017 | $699,003 | 843 | SANOFI-AVENTIS U.S. LLC ($205,067) |
All Payment Transactions
4,207 individual payment records from CMS Open Payments — Page 1 of 169
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Automated insulin delivery system | ||||||
| 12/30/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: Automated insulin delivery system | ||||||
| 12/24/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Diabetes Care | ||||||
| 12/24/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $12.41 | General |
| Category: Diabetes Care | ||||||
| 12/23/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: Endocrinology | ||||||
| 12/17/2024 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $15.39 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/09/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Durable Pump | ||||||
| 12/06/2024 | Alvogen Inc | TERIPARATIDE (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: OSTEOPOROSIS | ||||||
| 12/05/2024 | Senseonics, Incorporated | Eversense (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Endocrinology | ||||||
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Obesity | ||||||
| 12/04/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $10.93 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $90.92 | General |
| Category: Automated insulin delivery system | ||||||
| 12/03/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Automated insulin delivery system | ||||||
| 12/03/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $43.20 | General |
| Category: Automated insulin delivery system | ||||||
| 12/02/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: Endocrinology | ||||||
| 11/25/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $8.91 | General |
| Category: Durable Pump | ||||||
| 11/22/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: Endocrinology | ||||||
| 11/22/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $9.85 | General |
| Category: Durable Pump | ||||||
| 11/20/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: Gastroenterology | ||||||
| 11/13/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $116.01 | General |
| Category: Automated insulin delivery system | ||||||
| 11/13/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $64.80 | General |
| Category: Automated insulin delivery system | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus | SANOFI US SERVICES INC. | $68,535 | 3 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $64,576 | 4 |
| EVALUATION OF LY900014 IN A MEDTRONIC PUMP | Eli Lilly and Company | $47,800 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, CROSSOVER COMPARISON EVALUATING COMPATIBILITY AND SAFETY OF LY900014 AND INSULIN LISPRO WITH AN EXTERNAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION SYSTEM IN ADULT PATIENTS WITH TYPE 1 DIABETES PRONTO-PUMP | Eli Lilly and Company | $36,052 | 1 |
| AN EXPLORATORY STUDY ASSESSING TIME IN TARGET GLUCOSE RANGE USING A NEW TITRATION SCHEME OF LY900014 AND INSULIN DEGLUDEC IN PATIENTS WITH TYPE 1 DIABETES | Eli Lilly and Company | $28,606 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $7,070 | 1 |
| Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type | SANOFI-AVENTIS U.S. LLC | $6,527 | 5 |
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim b.v. | $1,331 | 3 |
| 99 | Theravance Biopharma Inc. | $1,000 | 1 |
| A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus | SANOFI-AVENTIS U.S. LLC | $785.40 | 2 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX4211 in Young Adult Patients With Type 1 Diabetes Mellitus and Eleva | SANOFI-AVENTIS U.S. LLC | $553.71 | 1 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 | SANOFI-AVENTIS U.S. LLC | $319.31 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 4,882 | 12,117 | $1.1M | $327,902 |
| 2022 | 29 | 4,868 | 12,001 | $1.1M | $332,206 |
| 2021 | 37 | 5,986 | 12,856 | $1.2M | $366,836 |
| 2020 | 32 | 5,004 | 10,106 | $1.0M | $276,082 |
Total Patients
20,740
Total Services
47,080
Medicare Billing
$1.3M
Procedure Codes
125
All Medicare Procedures & Services
125 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 602 | 1,481 | $399,870 | $136,856 | 34.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 35 | 3,480 | $156,600 | $64,417 | 41.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 344 | 833 | $91,630 | $21,589 | 23.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 109 | 238 | $41,650 | $14,804 | 35.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 575 | 1,380 | $69,000 | $13,063 | 18.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 337 | 482 | $37,568 | $7,912 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 105 | 131 | $26,200 | $7,885 | 30.1% |
| 82306 | Vitamin d-3 level | Office | 2023 | 198 | 245 | $24,500 | $7,082 | 28.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 90 | 173 | $16,435 | $6,683 | 40.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $21,375 | $6,007 | 28.1% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 294 | 409 | $32,720 | $5,355 | 16.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 35 | $17,500 | $4,773 | 27.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 312 | 449 | $22,450 | $4,638 | 20.7% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 332 | 477 | $23,850 | $4,209 | 17.6% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 142 | 234 | $37,440 | $3,884 | 10.4% |
| 82948 | Blood glucose (sugar) measurement using reagent strip | Office | 2023 | 357 | 717 | $14,340 | $3,527 | 24.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 285 | 394 | $15,760 | $2,992 | 19.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $7,905 | $2,772 | 35.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 17 | $6,120 | $2,398 | 39.2% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 245 | 334 | $35,070 | $1,885 | 5.4% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 229 | 305 | $10,675 | $1,545 | 14.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 40 | 85 | $10,625 | $936.56 | 8.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $3,355 | $860.58 | 25.7% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 46 | 53 | $5,300 | $770.39 | 14.5% |
| 82533 | Cortisol (hormone) measurement, total | Office | 2023 | 28 | 32 | $8,000 | $511.04 | 6.4% |
About Dr. Bruce Bode, M.D
Dr. Bruce Bode, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1841297751.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Bode, M.D has received a total of $2.9M in payments from pharmaceutical and medical device companies, with $103,990 received in 2024. These payments were reported across 4,207 transactions from 90 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.7M).
As a Medicare-enrolled provider, Bode has provided services to 20,740 Medicare beneficiaries, totaling 47,080 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 125 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Atlanta, GA
- Active Since 07/07/2005
- Last Updated 04/04/2023
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1841297751
Products in Payments
- SOLIQUA (Drug) $182,606
- TOUJEO (Drug) $167,629
- Tresiba (Drug) $154,165
- Ozempic (Drug) $150,954
- INVOKANA (Drug) $144,184
- TZIELD (Biological) $133,335
- AFREZZA (Drug) $129,164
- JARDIANCE (Drug) $121,571
- Eversense (Device) $108,675
- Minimed 670G System (Device) $105,937
- GVOKE PFS (Drug) $81,955
- RYBELSUS (Drug) $61,414
- FARXIGA (Drug) $60,656
- LYUMJEV (Drug) $56,024
- SOLIQUA 100/33 (Biological) $44,312
- SOLIQUA 100/33 (Drug) $41,981
- Minimed 630G (Device) $41,346
- InPen (Device) $41,102
- FIASP (Drug) $38,009
- Rybelsus (Drug) $31,550
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Atlanta
David Robertson, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $2.0M
Endocrinology, Diabetes & Metabolism $2.0M
Jonathan Ownby, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $297,304
Endocrinology, Diabetes & Metabolism $297,304
Guillermo Umpierrez, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $103,343
Endocrinology, Diabetes & Metabolism $103,343
Francisco Pasquel, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $88,785
Endocrinology, Diabetes & Metabolism $88,785
Priyathama Vellanki, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $61,485
Endocrinology, Diabetes & Metabolism $61,485
Dr. Scott Isaacs, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $57,100
Endocrinology, Diabetes & Metabolism $57,100